Glenmark Pharma gets USFDA nod for generic version of Nexium to treat acid reflux

Published On 2019-05-14 05:00 GMT   |   Update On 2019-05-14 05:00 GMT

The approved products Esomeprazole Magnesium delayed-release capsule is a generic version of AstraZeneca Pharmaceuticals' Nexium delayed-release capsules.


New Delhi: Glenmark Pharmaceuticals on May 14 said it has received final approval from the US health regulator for a generic version of AstraZeneca's Nexium, used to treat acid reflux.


Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (US FDA) for Esomeprazole Magnesium delayed-release capsules USP in the strengths of 20 mg and 40 mg, the company said in a BSE filing.


The approved products is a generic version of AstraZeneca Pharmaceuticals' Nexium delayed-release capsules.


Also Read: Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen




Citing IQVIA sales data, Glenmark said, Nexium delayed-release capsules, 20 mg and 40 mg achieved annual sales of around $395.1 million in the 12-month period ended March 2019.


The company said its current portfolio consists of 153 products authorised for distribution in the US and 58 ANDA's pending approval with the USFDA.



Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News